Effect analysis of preoperative neoadjuvant chemotherapy combined with enteral nutrition to tumor cell proliferative activity for gastric cancer patients

doi:10.3877/cma.j.issn.1674-0793.2015.06.011

Abstract

Abstract:

Objective

To discuss the effect of preoperative neoadjuvant chemotherapy combined with enteral nutrition for gastric cancer patients’ tumor cell proliferative activity.

Methods

One hundred and thirty-two gastric cancer patients in progressive stage were selected and divided randomly into observation group (preoperative neoadjuvant chemotherapy combined with enteral nutrition), and control group (simply preoperative neoadjuvant chemotherapy). All patients were recorded for and compared in tumor cell proliferative activity, immunity level and nutrition improvement before and after therapy.

Results

Before therapy, there was no difference between two group in tumor cell proliferative activity, immunity index, and nutriture. After therapy, compared with control group, CD4, CD4/CD8, NK, total protein, albumin, prealbumin, transferring, and hemoglobin all obviously increased in observation group, while DI, SPF, PI, CD8, NRS scores obviously decreased; the differences had statistical significance (P<0.05).

Conclusion

Preoperative neoadjuvant chemotherapy combined with enteral nutrition can decrease tumor cell proliferative activity in gastric cancer patients, and improve their immunity level and nutrition.

Key words: Gastric cancer, Progressive stage, Neoadjuvant chemotherapy, Enteral nutrition, Cell proliferative activity, Immunity level, Nutrition

Jintian Pei, Yun Lu, Bingxia Yin. Effect analysis of preoperative neoadjuvant chemotherapy combined with enteral nutrition to tumor cell proliferative activity for gastric cancer patients[J]. Chinese Archives of General Surgery(Electronic Edition), 2015, 09(06): 463-466.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhptwkxwx.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0793.2015.06.011

https://zhptwkxwx.cma-cmc.com.cn/EN/Y2015/V09/I06/463

Figures/Tables 4

References 13

1	张占东, 杨铁军, 孔烨, 等. 新辅助化疗结合肠内营养制剂支持对胃癌患者术前的影响研究[J/CD]. 中国医学前沿杂志:电子版, 2014, 6(10): 23-25.
2	Seo EH, Kim TO, Kim TG, et al. Efficacy and tolerability of split-dose PEG compared with split-dose aqueous sodium phosphate for outpatient colonoscopy: a randomized, controlled trial[J]. Dig Dis Sci, 2011, 56(10): 2963-2971.
3	于健春. "序贯疗法"优化手术后早期肠内营养[J]. 中华临床营养杂志, 2011, 19(3): 140-143.
4	邹淑雁, 李森龙, 杨曙光, 等. 胃癌患者术前营养风险筛查及预防性肠内营养支持[J]. 山东医药, 2011, 51(16): 74-75.
5	王金晶, 汪志明, 王震龙, 等. 鼻肠管在伴有胃出口梗阻的胃癌病人营养和化疗中的应用[J]. 肠外与肠内营养, 2012, 7(4): 56-58.
6	孟庆彬, 于健春, 康维明, 等. 空肠置管肠内营养对胃癌患者术后生活质量的影响[J]. 中国医学科学院学报, 2013, 35(3): 332-336.
7	Kim AR, Cho J, Hsu YJ, et al. Changes of quality of life in gastric cancer patients after curative resection: a longitudinal cohort study in Korea[J]. Ann Surg, 2012, 256(6): 1008-1013.
8	郭治. 远端胃大部切除术后长期生存胃癌患者的生活质量[J]. 中国医科大学学报, 2011, 40 (6): 568-570.
9	黄晋熙, 杨铁军, 王程虎, 等. 术前新辅助化疗结合肠内营养对胃癌患者肿瘤细胞增殖活性的影响[J]. 中国现代医学杂志, 2015, 25(3): 28-30.
10	秦环龙, 尹明明. 肠道微生态和肠道营养[J/CD]. 中华普通外科学文献:电子版, 2015, 9(3): 182-187.
11	杨平, 陈博, 伍晓汀. 胃癌住院患者营养风险及临床营养支持现状调查[J]. 中国普外基础与临床杂志, 2011, 18(6): 620-624.
13	龚龙波, 吕孝鹏, 孟良, 等. 便秘术后胃排空障碍及肠内营养支持治疗的应用[J/CD]. 中华普通外科学文献:电子版, 2013, 7(5): 367-369.

组别	例数	性别（例）		平均年龄（ ± s，岁）	病理分型（例）			TNM分期（例）
组别	例数	男	女	平均年龄（ ± s，岁）	中分化	低分化	黏液	Ⅱ期	Ⅲ期
观察组	66	42	24	56.3±1.5	28	20	18	28	38
对照组	66	44	22	56.2±1.7	26	23	17	29	37
统计值	?	0.133		0.148	0.312			0.031
P值	?	0.715		0.812	0.856			0.861

组别	例数	性别（例）		平均年龄（ ± s，岁）	病理分型（例）			TNM分期（例）
组别	例数	男	女	平均年龄（ ± s，岁）	中分化	低分化	黏液	Ⅱ期	Ⅲ期
观察组	66	42	24	56.3±1.5	28	20	18	28	38
对照组	66	44	22	56.2±1.7	26	23	17	29	37
统计值	?	0.133		0.148	0.312			0.031
P值	?	0.715		0.812	0.856			0.861

组别	例数	DI		SPF（%）		PI（%）
组别	例数	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
观察组	66	1.32±0.75	1.05±0.81	28.23±2.46	21.44±2.58	30.11±3.15	26.44±3.01
对照组	66	1.31±0.72	1.30±0.79 ^a	28.37±2.81	25.42±2.66 ^a	30.59±3.77	29.12±2.89 ^a
t值	?	0.078	2.381	0.305	8.725	0.794	5.218
P值	?	>0.05	<0.05	>0.05	<0.01	>0.05	<0.01

组别	例数	DI		SPF（%）		PI（%）
组别	例数	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
观察组	66	1.32±0.75	1.05±0.81	28.23±2.46	21.44±2.58	30.11±3.15	26.44±3.01
对照组	66	1.31±0.72	1.30±0.79 ^a	28.37±2.81	25.42±2.66 ^a	30.59±3.77	29.12±2.89 ^a
t值	?	0.078	2.381	0.305	8.725	0.794	5.218
P值	?	>0.05	<0.05	>0.05	<0.01	>0.05	<0.01

组别	例数	CD4		CD8		CD4/CD8		NK
组别	例数	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
观察组	66	42.81±6.22	46.38±7.21	26.77±8.15	22.34±5.36	1.58±0.42	2.15±0.54	9.44±5.10	13.85±7.44
对照组	66	42.56±6.47	42.89±6.99^a	27.10±7.92	26.20±5.10 ^a	1.56±0.47	1.69±0.59 ^a	9.51±5.27	10.11±6.32 ^a
t值	?	0.226	2.823	0.236	4.238	0.258	4.672	0.078	3.112
P值	?	>0.05	<0.01	>0.05	<0.01	>0.05	<0.01	>0.05	<0.01

Please choose a citation manager

Content to export